Kenvue will introduce the Kenvue Pediatrics platform of brands at the 2023 American Academy of Pediatrics (AAP) National Conference & Exhibition 2023 set for October 20-24 at the Walter E. Washington Convention Center in Washington, D.C. Kenvue will share data and insights about its infant-care science across multiple consumer needs from its exhibit hall booth.
As part of Kenvue’s inaugural attendance at AAP, iconic brands including Johnson’s®, Aveeno® Baby, Zyrtec®, Tylenol®, Motrin®, and the Zarbee’s®[i] health and wellness products will be showcased.
The company’s pediatrics portfolio, which includes gentle bath and body products as well as pediatric-formulated oral and topical medications and health solutions, features oat-enriched skin care and other emollients that soothe and protect against skin conditions including eczema. Featured formulations have been shown to promote sleep (when researched in a bedtime routine), relieve pain or fever, ease allergy symptoms, alleviate cough and support the immune system.
“Pediatricians, parents and caregivers have the power to immeasurably improve the trajectory of children’s lives by intervening early to support their well-being from their very first days,” said Caroline Tillett, Chief Scientific Officer at Kenvue. “We are fiercely committed to providing unparalleled research and development, creating tools for all the moments that matter throughout childhood.”
Presentation topics
Promoting sleep
Improved infant sleep has been identified as the top baby-care consumer need. Kenvue scientists and leading experts will discuss the importance of bedtime and naptime routines for newborns, infants, and toddlers. Jodi A. Mindell, Ph.D., a clinical psychologist, Associate Director of the Sleep Center at Children’s Hospital of Philadelphia, and a professor at Saint Joseph’s University, will also share new research on how the management of atopic dermatitis positively impacts sleep in young children.
“Sleep is key, not only for babies but for their parents,” said Dr. Mindell. “Pediatricians and parents should be aware of the importance of sleep routines and the benefits of treating itchy, dry skin to help everyone get a good night’s sleep.”
Protecting skin
Skin is the body’s largest organ and serves as the first line of defense against invaders of the immune system, including allergens — but it’s very vulnerable in newborns as it is still developing. Kenvue’s presentations will highlight the proven advantages of the multifunctional benefits of oatmeal — the only single ingredient over-the-counter skin protectant indicated by the U.S. Food & Drug Administration for the treatment of eczema symptoms1 — in soothing the skin barrier in babies and the importance of early skin care intervention.
Paul S. Horowitz MD, a pediatrician with Discovery Pediatrics in Valencia, California, will present research on the benefits of early emollient usage to protect the newborn skin barrier, including results from the recent STOP-AD randomized, controlled trial,2 which demonstrated that twice daily use of an oat-based high-glycerin emollient from as early as day two for two months provides positive skin outcomes in the first year of life among infants who are at risk of developing eczema.
Influential speakers and discussions
A total of 10 talks on topics ranging from pediatric skin, sleep, allergies and more will be shared at Kenvue’s Science Theater in Booth #2403 throughout the conference. Speakers will include several of the company’s leaders and scientists, as well as three distinguished researchers: Jodi A. Mindell, Ph.D., Paul S. Horowitz, MD, and Mona Amin, DO., FAAP., a board certified pediatrician, and a faculty moderator and resident preceptor for Memorial Hospital-Joe DiMaggio Children’s Hospital in Hollywood, Florida.
For more information or to set up interviews with Kenvue scientists or presenters during or after AAP, please contact media relations at the email address below. Further information on Kenvue Pediatrics will be available at kenvuepediatrics.com starting October 17, 2023.
###
References
1. FDA.gov. CFR - Code of Federal Regulations Title 21, Chapter I, Subchapter D, Part 347 Skin protectant drug products for over-the-counter human use. Updated June 7, 2023. Accessed August 28, 2023. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=347
2. Chaoimh CN, Lad D, Nico C, et al. Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants–The STOP-AD randomised controlled trial. Allergy. 2023;78(4):984-994. doi: 10.1111/all.15491.
Contacts
Media Relations:
Meghan Harding
[email protected]
[i] Johnson’s®, Aveeno® Baby, Zyrtec®, Tylenol®, Motrin® and Zarbee’s® are brands of Johnson & Johnson Consumer Inc., a subsidiary of Kenvue.